TKPHF TAKEDA PHARMACEUTICAL CO LTD
- 26.830
- +1.290+5.05%
TAKEDA PHARMACEUTICAL CO LTD News
6-K: Report of foreign private issuer (related to financial reporting)
Kirin HD, Takeda Pharmaceutical, Sumitomo, SoftBank (9th)
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------5/9 (Thu) ＜1375＞Snow Country Maitake ＜1720＞Tokyu Construction＜1738＞Nittoh ＜1764＞Kudo Construction＜1788＞Santo Kogyo ＜1799＞Daiichi Kenset＜1869＞Meikouken ＜1870＞Yahagi Kenset＜1929
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
Takeda Pharmaceutical GAAP EPS of ¥94.00, Revenue of ¥3212.9B; Reaffirms FY23 Guidance
Cognizant Helping to Modernize Infrastructure and Application Management as Part of Takeda's Digital Transformation
ImmunoGen Inks Deal With Takeda for Cancer Drug Elahere
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE:TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties' collab
Takeda Pharmaceutical Non-GAAP EPS of ¥558.00, Revenue of ¥4.03B; Initiates FY23 Guidance
Takeda's Entyvio Meets Primary Endpoint in Post-market Study
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced results from a Phase 2b clinical trial of TAK-279 (NDI-034858) in patients with moderate-to-severe plaque psoriasis. The study met its primary and sec
Takeda Presents Vedolizumab Data For Preventing Graft-Versus-Host Disease In Stem Cell Transplant Patients
Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings.GRAPHITE (vedolizumab-3035) Phase 3 study designed to evaluat
Takeda Reports 13% Fall In Nine Month Operating Profit, Keeps Annual Guidance Unchanged
Takeda Pharmaceutical Co Ltd (NYSE:TAK) reported a 13% drop in operating earnings to ¥401.9 billion for the nine months ending December. However, it reaffirmed its profit outlook for FY22.Operating pr
Takeda Pharmaceutical Non-GAAP EPS of ¥456.00, Revenue of ¥3071.3B; Reaffirms Full-year Guidance
Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study
Takeda Pharmaceutical Co Ltd (NYSE:TAK) and Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced topline results from the Phase 2 SEQUOIA study of fazirsiran (TAK-999/ARO-AAT) for liver disease assoc
Astellas Pharma, Eisai, Daiichi Sankyo and Takeda Join Hands to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
Takeda Pharmaceutical Co Ltd (NYSE:TAK) will acquire NDI-034858 from Nimbus Therapeutics, an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor for multiple autoimmune diseases. It is in an
Takeda's Dengue Vaccine Candidate Under FDA Priority Review
The FDA has accepted and granted priority review to Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Biologics License Application (BLA) for TAK-003, the company's investigational dengue vaccine candidate. I
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Phase 3 PhALLCON trial of Iclusig (ponatinib) met its primary endpoint in newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ A
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
Finch Therapeutics Group Inc (NASDAQ:FNCH) will regain full development and commercial rights to FIN-524 (previously known as TAK-524) and FIN-525 from Takeda Pharmaceutical Company Ltd (NYSE:TAK). Fo
Analysis
Price Target
No Data
